Clinical Trials

Sponsor: SWOG

Sponsor Study ID: S1900E

Study Title: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

NCT Number: NCT04625647

Phase: II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Lung

Study Objectives: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.